Has Devina Mehta, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,049 in general payments to Devina Mehta, MD across 199 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Devina Mehta, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Devina Mehta, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Devina Mehta, MD

Dermatology · Boston, MANPI 1760042196

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 199 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,286, more than ten times the $96 reported in 2023.

$4,049in general payments, 2019–2025

Across 199 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Arcutis Biotherapeutics, Inc.$482
AbbVie$382
Sun Pharmaceutical Industries Inc.$356
Novartis$334
UCB, Inc.$328
Lilly USA, LLC$320
plus $2K from 19 others

$52,144in research payments, 2019–2025

Across 6 payments — averaging $8690.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi Pasteur Inc.$52K

What the payments were for

Food & beverage$3,84095%
Education$2095%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Arcutis Biotherapeutics, Inc.	22	$482
AbbVie	14	$382
Sun Pharmaceutical Industries Inc.	22	$356
Novartis	25	$334
UCB, Inc.	19	$328
Lilly USA, LLC	14	$320
Galderma Laboratories, L.p.	12	$310
Johnson & Johnson	7	$211
Incyte Corporation	14	$211
Dermavant Sciences, Inc.	5	$190
E.r. Squibb & Sons, L.L.C.	6	$163
Regeneron Healthcare Solutions, Inc.	6	$152
Sanofi	8	$149
LEO Pharma Inc.	5	$109
Pfizer	4	$74
Biofrontera Inc.	3	$49
Fidia Pharma USA Inc.	2	$46
Botanix SB Inc	2	$38
Amgen	2	$37
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$30
Kyowa Kirin, Inc.	1	$19
Verrica Pharmaceuticals Inc.	1	$15
Merz North America, Inc.	1	$15
Journey Medical Corporation	1	$15
Boehringer Ingelheim	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZORYVE$217
VTAMA$140
BOTOX$136
EBGLYSS$116
NEMLUVIO$100

How this compares

$4,049 in reported general payments places this provider in the 70th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$8,582

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mupirocin	12	$109

Paid to pharmacies, not to this prescriber.

Other dermatology in Boston

Alexandra KimballBoston$680K
Arash MostaghimiBoston$591K
Brian HiblerBoston$498K
Maryanne SennaBoston$430K
Ruth Ann VleugelsBoston$368K
Gabriela CobosBoston$343K
Martina PorterBoston$220K
Mathew AvramBoston$209K
Emmy GraberBoston$159K
Neelam VashiBoston$156K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →